BioCatalystWatch
SLGLWorkspace / SLGL / OverviewCompany library
Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd. (SLGL)

Website

Price
Market cap
Next catalystLate November 2026SGT-610 — SGT-610-01 in Gorlin syndrome · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

SGT-610

SMO

SGT-610

SMO

PreINDP1P2P3FilingApproved
Upcoming / outlook

SGT-610

SMO

SGT-210

EGFR

Upcoming / outlook

SGT-310

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SGT-210

EGFR

Upcoming / outlook

SGT-610

SMO

PreINDP1P2P3FilingApproved
Upcoming / outlook

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

SGT-610

SMO

SGT-610

SMO

SGT-310

PreINDP1P2P3FilingApproved

Other pipelines

SGT-210

EGFR

PreINDP1P2P3FilingApproved
SGT-210

EGFR

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SLGL PR & News

SLGL SEC archive